Background and Purpose-Despite clear evidence that blood pressure (BP) lowering is effective for prevention of cardiovascular events among patients with isolated systolic hypertension and systolic-diastolic hypertension, there is ongoing uncertainty about its effects in those with isolated diastolic hypertension. The objective of the present analysis is to determine whether BP lowering provides benefits to patients with isolated diastolic hypertension. Methods-Patients with cerebrovascular disease and hypertension at baseline (nϭ4283) were randomly assigned to either active treatment (perindopril in all participants plus indapamide for those with neither an indication for nor a contraindication to a diuretic) or matching placebo(s). The primary outcome was total major vascular events. Results-There were 1923 patients with isolated systolic hypertension (systolic BP Ն140 mm Hg and diastolic BP Ͻ90 mm Hg), 315 with isolated diastolic hypertension (systolic BP Ͻ140 mm Hg and diastolic BP Ն90 mm Hg), and 2045 with systolic-diastolic hypertension (systolic BP Ն140 mm Hg and diastolic BP Ն90 mm Hg) at baseline. Active treatment reduced the relative risk of major vascular events by 27% (95% CI, 10% to 41%) among patients with isolated systolic hypertension, by 28% (Ϫ29% to 60%) among those with isolated diastolic hypertension, and by 32% (17% to 45%) among those with systolic-diastolic hypertension. There was no evidence of differences in the magnitude of the effects of treatment among different types of hypertension (P homogeneityϭ0.89). Conclusions-BP lowering is likely to provide a similar level of protection against major vascular events for patients with isolated diastolic hypertension as for those with isolated systolic hypertension and systolic-diastolic hypertension. Clinical Trial Registration Information-This trial was not registered because patients were enrolled before July 1, 2005.
R ecent large-scale observational studies have demonstrated that isolated diastolic hypertension (IDH) as well as isolated systolic (ISH) and systolic-diastolic hypertension (SDH) is associated with a significantly increased risk of cardiovascular disease. 1, 2 However, patients with IDH have been shown to be less likely to receive blood pressure (BP) lowering treatment than those with ISH or SDH. 1, 3 One likely reason is ongoing uncertainty about the beneficial effects of BP lowering treatment in patients with IDH, because it is less common and there is a greater clinical emphasis placed on the elevated systolic component of BP. 4 The objective of the present analysis was to determine whether BP lowering provides the same protection among patients with IDH as it does among patients with other forms of hypertension.
Methods

Study Design
The design of Perindopril Protection Against Recurrent Stroke Study (PROGRESS) has been described in detail elsewhere. 5 Briefly, 6105 participants with cerebrovascular disease who had no clear indication for, or contraindication to, an angiotensin-converting enzyme inhibitor were recruited. In the present analysis, the 4283 participants with hypertension (systolic BP [SBP] Ն140 mm Hg and/or diastolic BP [DBP] Ն90 mm Hg) at baseline were included. Participants were randomly assigned to active treatment (2 to 4 mg perindopril for all participants plus 2 to 2.5 mg indapamide for those with neither an indication for nor a contraindication to a diuretic) or matching placebo(s).
The institutional ethics committee of each collaborating center approved the trial, and all participants provided written, informed consent. Procedures followed were in accordance with institutional guidelines.
Hypertension Subtype
BP was measured, to the nearest 2 mm Hg, after 5 minutes of quiet rest in the seated position using a standard mercury sphygmomanometer. After an interval of at least 2 minutes, the measurement was repeated and the results averaged. 
Outcomes
The outcome studied here was major vascular event (nonfatal stroke, nonfatal myocardial infarction, or vascular death).
Statistical Analysis
The effects of randomized treatment on events were estimated using univariate Cox proportional hazards models according to the principle of intention to treat. Treatment effects in subgroups were standardized for the proportions of the study population for whom combination (58%) or single-drug therapy (42%) was prescribed. 5 A comparison of treatment effects across patient groups was done by adding an interaction term to the statistical model.
Results
There were 1923 patients with ISH, 315 with IDH, and 2045 with SDH at baseline. Patients with IDH were younger and more likely to be male and Asian (Table) . Over a mean follow-up of 3.9 years, 794 major vascular events occurred. During follow-up, mean BP difference between randomized groups was 8.8/3.8, 6.2/2.3, and 10.0/4.4 mm Hg for patients with ISH, IDH and SDH, respectively (P homogeneityϭ0.003 for SBP and 0.02 for DBP). Active treatment reduced the relative risk of major vascular events by 27% (95% CI, 10% to 41%) among patients with ISH, by 28% (Ϫ29% to 60%) among those with IDH, and by 32% (17% to 45%) among those with SDH ( Figure) . There was no evidence of differences in magnitude of the effects of treatment among different types of hypertension (P homogeneityϭ0.89). Comparable effects of randomized treatment on major vascular events were observed between patient groups defined by age (Ͻ65 versus Ն65 years), sex, geographic region, and baseline use of antihypertensive therapy for each hypertension subtype (all P homogeneity Ͼ0.1). BP reductions and risk reductions were consistently greater with combination therapy than single-drug therapy (mean SBP difference 12.3 versus 3.9 mm Hg, 7.7 versus 4.3 mm Hg, and 13.5 versus 5.2 mm Hg; relative risk reduction of major vascular events 34% versus 16%, 63% versus Ϫ78%, and 
Figure.
Effects of randomized treatment on the risks of major vascular events by hypertension subtype. Solid boxes represent estimates of treatment effect; horizontal lines, 95% confidence interval (CI); a diamond, the estimate and 95% CI for overall effect. Areas of the boxes are proportional to the number of events. ISH indicates isolated systolic hypertension; IDH, isolated diastolic hypertension; SDH, systolic-diastolic hypertension; CI, confidence interval.
45% versus 10%; P homogeneityϭ0.26, 0.009, and 0.03 for patients with ISH, IDH, and SDH, respectively).
Discussion
The main results from the PROGRESS trial showed that routine BP lowering treatment reduced the risk of major vascular events by 26% among patients with cerebrovascular disease. 5 These analyses extend the findings of the main report and suggest that BP lowering is likely to be similarly beneficial in patients with IDH as in those with ISH and SDH. Like with the main results, 5 the reductions in BP and major vascular events were greater in patients receiving combination therapy. These results support the current guidelines for management of hypertension, 6, 7 which recommend therapeutic approaches based on DBP as well as SBP.
Although this appears to be the first article to report the beneficial effects of BP lowering in IDH to date, the number of events recorded among participants with IDH was limited and insufficient to provide separately significant results.
Conclusions
BP lowering is likely to provide protection against major vascular events for patients with IDH as well as those with ISH and SDH. Although additional data would much more clearly define the effects of BP lowering in patients with IDH, the evidence provided here suggests that clinicians should strongly consider initiation of BP lowering therapy among patients with IDH.
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